<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04683757</url>
  </required_header>
  <id_info>
    <org_study_id>2017-KY-19</org_study_id>
    <nct_id>NCT04683757</nct_id>
  </id_info>
  <brief_title>The Establishment of a Survival Prediction Model for ER Positive / HER-2 Negative Advanced Breast Cancer</brief_title>
  <official_title>A Prospective Cohort Study： the Establishment of a Survival Prediction Model for ER Positive / HER-2 Negative Advanced Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ying Wang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project is a prospective, clinical cohort study initiated by researchers to study the&#xD;
      high-risk factors affecting the overall survival of newly diagnosed ER + / HER2 - advanced&#xD;
      breast cancer patients and to establish a prediction model of ER + / HER2 - advanced breast&#xD;
      cancer patients affecting overall survival. This project is the first prospective prediction&#xD;
      model for the survival of patients with advanced breast cancer, and it is also the first time&#xD;
      to establish a survival prediction model for ER-positive / HER2 negative advanced breast&#xD;
      cancer suitable for China's national conditions. According to the survival outcome predicted&#xD;
      by the model, the newly diagnosed ER positive / HER2 negative advanced breast cancer was&#xD;
      divided into three groups: low, medium, and high risk, which provided an important&#xD;
      theoretical basis for further design of randomized controlled clinical research and guidance&#xD;
      of individualized precise treatment scheme for different groups in the future.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival，OS</measure>
    <time_frame>5 years</time_frame>
    <description>The time from the beginning of treatment to the death of the patient</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor specific survival time, CSS</measure>
    <time_frame>5 years</time_frame>
    <description>The follow-up started from the first day of confirmed recurrence and metastasis. The end point of follow-up was the death caused by tumor related causes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival，PFS</measure>
    <time_frame>2 years</time_frame>
    <description>The time from the beginning of treatment to the progression or death of the patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5-year survival rate</measure>
    <time_frame>5 years</time_frame>
    <description>the survival rate in 5 years</description>
  </secondary_outcome>
  <enrollment type="Anticipated">288</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Establishment of a Survival Prediction Model</intervention_name>
    <description>a nomogram to predict the survival of patients with ER positive / HER-2 negative advanced breast cancer</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      The target of this study is to detect the gene mutation of tumor tissue or peripheral blood&#xD;
      circulation tumor DNA of tumor patients. 10ml of tissue or fresh peripheral blood should be&#xD;
      collected as the test sample and stored at room temperature. On the same day, it was sent to&#xD;
      the &quot;cell and molecular diagnosis center&quot; of our hospital for DNA isolation and extraction,&#xD;
      secondary sequencing, and detection of related biomarkers, such as erbB2 / TP53 / PIK3CA /&#xD;
      ErbB4 / CCND1.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        breast cancer&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. At the time of signing the informed consent form, 18 years old ≤ 70 years old, female&#xD;
&#xD;
          2. ER positive breast cancer confirmed by pathology: ER positive (≥ 1%) by&#xD;
             immunohistochemistry&#xD;
&#xD;
          3. Newly diagnosed advanced patients, including patients with early breast cancer who&#xD;
             have evidence of recurrence and metastasis after adjuvant therapy and patients with&#xD;
             stage IV breast cancer at the first visit&#xD;
&#xD;
          4. Patients who are willing to receive follow-up treatment in the research center.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. ErbB-2 gene amplification was recorded by fish (defined as HER2 / CEP17 ratio ≥ 2) or&#xD;
             chromogenic in situ hybridization (CISH) or IHC (defined as ihc3 +, or ihc2 +&#xD;
             confirmed by fish or CISH) was used to record HER2 positive tumors.&#xD;
&#xD;
          2. Any form of anti-cancer treatment has been carried out for recurrent or metastatic&#xD;
             lesions&#xD;
&#xD;
          3. Combined with other malignant tumors or had other malignant tumors in recent 5 years&#xD;
&#xD;
          4. Patients with nervous system disorders caused by diseases or obvious mental disorders&#xD;
             will affect patients' right to know, compliance or make them in a dangerous state&#xD;
&#xD;
          5. Patients with life expectancy less than 3 months&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ying Dr. Wang, doctor</last_name>
    <phone>86-20-34070499</phone>
    <email>wangy556@mail.sysu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jianli Zhao</last_name>
    <phone>86-20-34070870</phone>
    <email>zhaojli5@mail.sysu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun Yat Sen Memorial Hospital，Sun Yat sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen Memorial Hospital， Sun Yat-sen University</name>
      <address>
        <city>Guanzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ying Wang</last_name>
      <phone>86-020-34070870</phone>
      <email>wangy556@mail.sysu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Jianli Zhao</last_name>
      <phone>86-020-34070499</phone>
      <email>zhaojli5@mail.sysu.edu.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 19, 2020</study_first_submitted>
  <study_first_submitted_qc>December 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2020</study_first_posted>
  <last_update_submitted>December 19, 2020</last_update_submitted>
  <last_update_submitted_qc>December 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Ying Wang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>a Survival Prediction Model</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

